(NASDAQ:HUMA), – The ATEV(TM) was observed to have superior duration of use over 24 months compared to autogenous fistula in high-need subgroups with historically poor outcomes with AV fistula procedures – – The significantly longer duration of ATEV use in these high-need patients could greatly reduce reliance on catheters for dialysis access, a major cause […]

First-in-Human (FIH) Trial at 36 Months: 37% reduction in mean intraocular pressure (IOP) in evaluable patients across all dose groups with 95% of patients off all topical IOP-lowering drops 100% of evaluable patients achieved 20/30 or better Best Corrected Distance Visual Acuity (BCDVA) No product-related adverse events (AEs) were reported Phase I/II Trial at 3

(NasdaqGM:AVBP), Final Phase 1b results presented at World Lung Conference highlight the potential of firmonertinib to address unmet needs in EGFR PACC mutant NSCLC Received FDA IND clearance for ARR-217, a CDH-17 targeted ADC, with ongoing Phase 1 study in China Establised commercial leadership within excutive team with appointment of Brent S. Rice as Chief

(NASDAQ:FDMT), Entered strategic partnership with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of 4D-150 in the APAC region; to receive $85 million in upfront cash and expects to receive at least $50 million from cost sharing Announced positive long-term safety and efficacy data with 1.5 to 2 years of follow-up from the Phase

Mersana Therapeutics to Host Third Quarter 2025 Conference Call on November 14, 2025 GlobeNewswire November 10, 2025 CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it

Aqua Metals and Westwin Elements Sign LOI for U.S.-Produced Nickel Carbonate Supply Agreement outlines plans for one of the first domestic sources of battery-grade nickel carbonate GlobeNewswire November 10, 2025 RENO, Nev., Nov. 10, 2025 (GLOBE NEWSWIRE) — Aqua Metals, Inc. (NASDAQ: AQMS), a pioneer in sustainable battery metals recycling and refining, today announced a

(NASDAQ:ATYR), SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at the Piper Sandler 37th Annual

Madrigal Presents New Data Demonstrating Rezdiffra(R) (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis GlobeNewswire November 10, 2025 Rezdiffra(R) treatment significantly improved liver stiffness, fibrosis biomarkers, and markers of clinically significant portal hypertension risk in patients with compensated MASH cirrhosis Rezdiffra also improved disease-specific quality of life measures

(NASDAQ:KYTX), EMERYVILLE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) — Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the Jefferies Global Healthcare Conference in London, United Kingdom on Monday, November 17,

Disguise and Aniplex Announce Expanded Licensing Agreement for Demon Slayer: Kimetsu no Yaiba Costumes and Accessories GlobeNewswire November 10, 2025 POWAY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) — Disguise, Inc., the global costume division of leading toy and consumer products company JAKKS Pacific, Inc. (NASDAQ: JAKK), today announced the expansion of its multi-year licensing agreement